Assaf-Harofeh Medical Center
shamir.org.ilTotal trials
262
Active
36
Phase 3
9
Total enrollment
90,557
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 8 of 8 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Tranexamic acid | — | — | — | — | — | 2 | |
| Standard | — | — | — | — | — | 1 | |
| Dexmedetomidine | — | — | — | — | 2 | ||
| Sodium Bicarbonate | — | — | — | — | — | 1 | |
| Saline | — | — | — | — | — | 1 | |
| Propranolol and etodolac | — | — | — | — | — | 2 | |
| Lidocaine | — | — | — | — | — | 2 | |
| Ketalar | — | — | — | — | — | 1 |
Next readouts
- 2025-12
- 2026-04-30
- 2026-06-30
- 2026-09-01
- 2027-02-28
- 2027-12-01
Top conditions
- Fever6
- T1DM6
- Fibromyalgia6
- Diabetes5
- Hyperbaric Oxygen Therapy5
- Anxiety5
- Infertility5
- Pain5
Frequently asked questions about Assaf-Harofeh Medical Center
- How many clinical trials does Assaf-Harofeh Medical Center have on ClinicalTrials.gov?
- Assaf-Harofeh Medical Center is listed as the lead sponsor on 262 clinical trials in ClinicalTrials.gov, 36 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Assaf-Harofeh Medical Center's trials are in Phase 3?
- 9 of Assaf-Harofeh Medical Center's trials are in Phase 3, spread across 8 active drug programs.
- What therapeutic areas does Assaf-Harofeh Medical Center focus on?
- Assaf-Harofeh Medical Center's most-studied conditions on ClinicalTrials.gov are Fever, T1DM, Fibromyalgia, Diabetes, Hyperbaric Oxygen Therapy.
- When are Assaf-Harofeh Medical Center's next clinical trial readouts?
- Assaf-Harofeh Medical Center has 6 upcoming primary-completion readouts tracked here; the soonest is “Intranasal Dexmedetomidine for Pain Management During Screening for Retinopathy of Prematurity”, expected around 2025-12.